Dronabinol 2.5mg, 5mg, 10mg; caps; contains sesame oil.
Dronabinol 5mg/mL; oral soln; contains 50% w/w dehydrated alcohol, 5.5%w/w propylene glycol.
Dronabinol, a pharmaceutical formulation of the psychoactive component of marijuana, produces a longer duration of pain relief than smoked marijuana.
The FDA has approved Syndros (dronabinol oral solution) for the treatment of anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.
Syndros is anticipated to launch in the second half of 2017. It will be available as a 5mg/mL strength oral solution.
"Expanded and pivotal clinical trials must still be conducted to fully establish the best approach to cannabinoid therapy in obstructive sleep apnea," said lead author Professor David Carley.
Syndros is the first FDA-approved dronabinol solution for oral administration, containing the pharmaceutical version of tetrahydrocannabinol (THC).
Watson has launched a generic version of Solvay's Marinol (dronabinol capsules) in 2.5mg, 5mg, and 10mg dosage strengths.
Continuous positive airway pressure (CPAP) remains the mainstay of medical treatment for OSA.
Areas of potential medical use of THC include the relief of spasticity in neurodegenerative diseases, for pain reduction, and for seizure control.